TAK 828

Drug Profile

TAK 828

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease

Most Recent Events

  • 01 Feb 2017 Takeda terminates a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)
  • 01 Jul 2016 Takeda initiates enrolment in a phase I trial for Crohn's disease (In volunteers) in USA (NCT02817516)
  • 27 Jun 2016 Takeda plans a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top